Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteraemia (SAFE trial): protocol for a randomised, controlled, open-label, non-inferiority trial comparing 4 and 6 weeks of antibiotic treatment

Autor: DTP Buis, CH van Werkhoven, MA van Agtmael, HI Bax, M Berrevoets, MGJ de Boer, MJM Bonten, JE Bosmans, J Branger, S Douiyeb, LBS Gelinck, E Jong, AJJ Lammers, JTM Van der Meer, JJ Oosterheert, E Sieswerda, R Soetekouw, JE Stalenhoef, TW Van der Vaart, EA Bij de Vaate, NJ Verkaik, MGA Van Vonderen, PJ De Vries, JM Prins, KCE Sigaloff

Publikováno v: BMJ open, 13(4):e068295. BMJ Publishing Group
BMJ Open, 13(4):e068295, 1-26. BMJ Publishing Group
Collaborators SAFE-trial study group 2023, ' Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteraemia (SAFE trial) : protocol for a randomised, controlled, open-label, non-inferiority trial comparing 4 and 6 weeks of antibiotic treatment ', BMJ Open, vol. 13, no. 4, e068295, pp. e068295 . https://doi.org/10.1136/bmjopen-2022-068295
BMJ Open, 13(4). BMJ Publishing Group
BMJ Open, 13(4):e068295. BMJ Publishing Group
Buis, D T P, Van Werkhoven, C H, Van Agtmael, M A, Bax, H I, Berrevoets, M, De Boer, M G J, Bonten, M J M, Bosmans, J E, Branger, J, Douiyeb, S, Gelinck, L B S, Jong, E, Lammers, A J J, Van Der Meer, J T M, Oosterheert, J J, Sieswerda, E, Soetekouw, R, Stalenhoef, J E, Van Der Vaart, T W, Bij De Vaate, E A, Verkaik, N J, Van Vonderen, M G A, De Vries, P J, Prins, J M & Sigaloff, K C E 2023, ' Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteraemia (SAFE trial) : Protocol for a randomised, controlled, open-label, non-inferiority trial comparing 4 and 6 weeks of antibiotic treatment ', BMJ Open, vol. 13, no. 4, e068295, pp. 1-26 . https://doi.org/10.1136/bmjopen-2022-068295

IntroductionA major knowledge gap in the treatment of complicatedStaphylococcus aureusbacteraemia (SAB) is the optimal duration of antibiotic therapy. Safe shortening of antibiotic therapy has the potential to reduce adverse drug events, length of ho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af21151bb8a9b51016d71c3255ece501
https://pure.amc.nl/en/publications/safe-shortening-of-antibiotic-treatment-duration-for-complicated-staphylococcus-aureus-bacteraemia-safe-trial(7669693a-f906-448b-b63f-7135141cbf37).html

Duke-ISCVID criteria in patients with negative blood cultures.

Autor: van der Vaart TW; Division of Infectious Diseases, Amsterdam University Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands.; Duke University Medical Center, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA., Fowler VG; Duke University Medical Center, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA., van der Meer JTM; Division of Infectious Diseases, Amsterdam University Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands.

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 May 03. Date of Electronic Publication: 2024 May 03.

The Utility of Risk Factors to Define Complicated Staphylococcus aureus Bacteremia in a Setting With Low Methicillin-Resistant S. aureus Prevalence.

Autor: van der Vaart TW; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Prins JM; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Goorhuis A; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Lemkes BA; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Sigaloff KCE; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Spoorenberg V; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Stijnis C; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Bonten MJM; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., van der Meer JTM; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Apr 10; Vol. 78 (4), pp. 846-854.

The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria.

Autor: Fowler VG; Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA.; Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA., Durack DT; Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA., Selton-Suty C; CHU of Nancy, Cardiology Department, CIC-EC, Nancy, France., Athan E; Department of Infectious Disease, Barwon Health and School of Medicine, Deakin University, Geelong, Australia., Bayer AS; Division of Infectious Diseases, The Lundquist Institute at Harbor-UCLA, Torrance, California, USA.; Department of Medicine, The Geffen School of Medicine at UCLA, Los Angeles, California, USA., Chamis AL; Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA., Dahl A; Department of Cardiology, Herlev-Gentofte University Hospital, Copenhagen, Denmark., DiBernardo L; Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA., Durante-Mangoni E; Department of Precision Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Naples, Italy., Duval X; AP-HP, Hôpital Bichat, Centre d'Investigation Clinique, INSERM CIC 1425, Université Paris Cité, IAME, INSERM, Paris, France., Fortes CQ; Infectious Diseases Department, Hospital Universitário Clementino Fraga Filho-Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil., Fosbøl E; The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark., Hannan MM; Clinical Microbiology Department, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland., Hasse B; Department of Infectious Diseases and Hospital Epidemiology, University Hospital, University of Zurich, Zurich, Switzerland., Hoen B; Department of Infectious Diseases and Tropical Medicine and Inserm CIC-1424, Université de Lorraine, APEMAC, Nancy, France., Karchmer AW; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Mestres CA; Department of Cardiothoracic Surgery and the Robert WM Frater Cardiovascular Research Centre, The University of the Free State, Bloemfontein, South Africa., Petti CA; Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA.; HealthSpring Global Inc, Bradenton, Florida, USA., Pizzi MN; Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Preston SD; Histopathology, Royal Papworth Hospital, Cambridge, United Kingdom., Roque A; Department of Radiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Vandenesch F; CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, INSERM, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.; Institut des agents infectieux, Hospices Civils de Lyon, Lyon, France., van der Meer JTM; Division of Infectious Diseases, Amsterdam UMC, Amsterdam, The Netherlands., van der Vaart TW; Division of Infectious Diseases, Amsterdam UMC, Amsterdam, The Netherlands., Miro JM; Infectious Diseases Service, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Aug 22; Vol. 77 (4), pp. 518-526.

Value of diagnosing immunological phenomena in patients with suspected endocarditis.

Autor: van der Vaart TW; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. t.w.vandervaart@amsterdamumc.nl.; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. t.w.vandervaart@amsterdamumc.nl., Heerschop LL; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands., Bouma BJ; Department of Cardiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands., Freudenburg W; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands., Bonten MJM; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands., Prins JM; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands., van der Meer JTM; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Publikováno v: Infection [Infection] 2023 Jun; Vol. 51 (3), pp. 705-713. Date of Electronic Publication: 2022 Nov 10.